Quantifying physical decline in juvenile neuronal ceroid lipofuscinosis (Batten disease)
- PMID: 22013180
- PMCID: PMC3233207
- DOI: 10.1212/WNL.0b013e318237f649
Quantifying physical decline in juvenile neuronal ceroid lipofuscinosis (Batten disease)
Abstract
Objective: To use the Unified Batten Disease Rating Scale (UBDRS) to measure the rate of decline in physical and functional capability domains in patients with juvenile neuronal ceroid lipofuscinosis (JNCL) or Batten disease, a neurodegenerative lysosomal storage disorder. We have evaluated the UBDRS in subjects with JNCL since 2002; during that time, the scale has been refined to improve reliability and validity. Now that therapies are being proposed to prevent, slow, or reverse the course of JNCL, the UBDRS will play an important role in quantitatively assessing clinical outcomes in research trials.
Methods: We administered the UBDRS to 82 subjects with JNCL genetically confirmed by CLN3 mutational analysis. Forty-four subjects were seen for more than one annual visit. From these data, the rate of physical impairment over time was quantified using multivariate linear regression and repeated-measures analysis.
Results: The UBDRS Physical Impairment subscale shows worsening over time that proceeds at a quantifiable linear rate in the years following initial onset of clinical symptoms. This deterioration correlates with functional capability and is not influenced by CLN3 genotype.
Conclusion: The UBDRS is a reliable and valid instrument that measures clinical progression in JNCL. Our data support the use of the UBDRS to quantify the rate of progression of physical impairment in subjects with JNCL in clinical trials.
Figures

Comment in
-
Measuring to improve: a new rating scale for Batten disease.Neurology. 2011 Nov 15;77(20):1779-80. doi: 10.1212/WNL.0b013e3182377e6f. Epub 2011 Oct 19. Neurology. 2011. PMID: 22013177 No abstract available.
Similar articles
-
The Unified Batten Disease Rating Scale (UBDRS): Validation and reliability in an independent CLN3 disease sample.Eur J Paediatr Neurol. 2022 May;38:62-65. doi: 10.1016/j.ejpn.2022.03.005. Epub 2022 Apr 4. Eur J Paediatr Neurol. 2022. PMID: 35427884 Free PMC article.
-
Methodology of clinical research in rare diseases: development of a research program in juvenile neuronal ceroid lipofuscinosis (JNCL) via creation of a patient registry and collaboration with patient advocates.Contemp Clin Trials. 2013 Jul;35(2):48-54. doi: 10.1016/j.cct.2013.04.004. Epub 2013 Apr 26. Contemp Clin Trials. 2013. PMID: 23628560 Free PMC article.
-
Genotype does not predict severity of behavioural phenotype in juvenile neuronal ceroid lipofuscinosis (Batten disease).Dev Med Child Neurol. 2010 Jul;52(7):637-43. doi: 10.1111/j.1469-8749.2010.03628.x. Epub 2010 Feb 19. Dev Med Child Neurol. 2010. PMID: 20187884 Free PMC article.
-
Current Insights in Elucidation of Possible Molecular Mechanisms of the Juvenile Form of Batten Disease.Int J Mol Sci. 2020 Oct 29;21(21):8055. doi: 10.3390/ijms21218055. Int J Mol Sci. 2020. PMID: 33137890 Free PMC article. Review.
-
Atypical late infantile and juvenile forms of neuronal ceroid lipofuscinosis and their diagnostic difficulties.Folia Neuropathol. 1997;35(2):73-9. Folia Neuropathol. 1997. PMID: 9377079 Review.
Cited by
-
Classification and natural history of the neuronal ceroid lipofuscinoses.J Child Neurol. 2013 Sep;28(9):1101-5. doi: 10.1177/0883073813494268. Epub 2013 Jul 9. J Child Neurol. 2013. PMID: 23838030 Free PMC article. Review.
-
Natural History Studies in NCL and Their Expanding Role in Drug Development: Experiences From CLN2 Disease and Relevance for Clinical Trials.Front Neurol. 2022 Feb 8;13:785841. doi: 10.3389/fneur.2022.785841. eCollection 2022. Front Neurol. 2022. PMID: 35211079 Free PMC article. Review.
-
Reliability and validity of the Wolfram Unified Rating Scale (WURS).Orphanet J Rare Dis. 2012 Nov 14;7:89. doi: 10.1186/1750-1172-7-89. Orphanet J Rare Dis. 2012. PMID: 23148655 Free PMC article.
-
Short-Term Administration of Mycophenolate Is Well-Tolerated in CLN3 Disease (Juvenile Neuronal Ceroid Lipofuscinosis).JIMD Rep. 2019;43:117-124. doi: 10.1007/8904_2018_113. Epub 2018 Jun 20. JIMD Rep. 2019. PMID: 29923092 Free PMC article.
-
Quantitative telemedicine ratings in Batten disease: implications for rare disease research.Neurology. 2011 Nov 15;77(20):1808-11. doi: 10.1212/WNL.0b013e3182377e29. Epub 2011 Oct 19. Neurology. 2011. PMID: 22013181 Free PMC article.
References
-
- Boustany RM. Neurology of the neuronal ceroid- lipofuscinoses: late infantile and juvenile types. Am J Med Genet 1992; 42: 533–535 - PubMed
-
- Consortium TIBD. Isolation of a novel gene underlying Batten disease, CLN3. Cell 1995; 82: 949–957 - PubMed
-
- Mitchison HM, Munroe PB, O'Rawe AM, et al. Genomic structure and complete nucleotide sequence of the Batten disease gene, CLN3. Genomics 1997; 40: 346–350 - PubMed
-
- Phillips SN, Benedict JW, Weimer JM, Pearce DA. CLN3, the protein associated with Batten disease: structure, function and localization. J Neurosci Res 2005; 79: 573–583 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical